Citrini Research reported that an unreleased version of Anthropic's Claude could not create scorpion antivenom. The investment research firm partnered with Anthropic to test whether the AI model could revolutionize drug development by designing a new medication from scratch.
Experts told The Verge that the model produced promising starting points but failed to generate anything close to an actual drug. Citrini Research acknowledged that its team did not claim expertise in AI as it related to biology, yet proceeded with the experiment. The firm published a blog post titled "We Wanted to Use Claude to Create a New Drug. Here's What Happened" to document the attempt and its outcome.